Have a personal or library account? Click to login
Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis Cover

Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis

Acta Pharmaceutica
Volume 74 (2024): Issue 3 (September 2024)
By:
Open Access
|Sep 2024

References

  1. R. L. Siegel, K. D. Miller, H. E. Fuchs and A. Jemal, Cancer statistics, 2022, <em>CA</em> <bold>72</bold>(1) (2022) 7–33; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3322/caac.21708" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3322/caac.21708</a>">https://doi.org/10.3322/caac.21708</ext-link>
    Search in Google ScholarBack to article
  2. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries, <em>CA</em> <bold>71</bold>(3) (2021) 209–249; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3322/caac.21660" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3322/caac.21660</a>">https://doi.org/10.3322/caac.21660</ext-link>
    Search in Google ScholarBack to article
  3. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, <em>J. Hepatol.</em> <bold>69</bold>(1) (2018) 182–236; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2018.03.019" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2018.03.019</a>">https://doi.org/10.1016/j.jhep.2018.03.019</ext-link>
    Search in Google ScholarBack to article
  4. J. K. Heimbach, L. M. Kulik, R. S. Finn, C. B. Sirlin, M. M. Abecassis, L. R. Roberts, A. X. Zhu, M. H. Murad and J. A. Marrero, AASLD guidelines for the treatment of hepatocellular carcinoma, <em>Hepatology</em> <bold>67</bold>(1) (2018) 358–380; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1002/hep.29086" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/hep.29086</a>">https://doi.org/10.1002/hep.29086</ext-link>
    Search in Google ScholarBack to article
  5. Y. Chang, S. J. Yu, H. C. Kim, Y. B. Lee, E. J. Cho, J. H. Lee, Y. J. Kim, J. W. Chung and J. H. Yoon, Reappraisal of portal vein tumor thrombosis as a prognostic factor for patients with hepatocellular carcinoma, <em>Gut Liver</em> <bold>18</bold>(1)(2024) 156–164; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.5009/gnl230057" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.5009/gnl230057</a>">https://doi.org/10.5009/gnl230057</ext-link>
    Search in Google ScholarBack to article
  6. A. Forner, M. Reig and J. Bruix, Hepatocellular carcinoma, <em>Lancet</em> <bold>391</bold>(10127) (2018) 1301–1314; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/s0140-6736(18)30010-2" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/s0140-6736(18)30010-2</a>">https://doi.org/10.1016/s0140-6736(18)30010-2</ext-link>
    Search in Google ScholarBack to article
  7. D. Takizawa, S. Kakizaki, N. Sohara, K. Sato, H. Takagi, H. Arai, K. Katakai, A. Kojima, Y. Matsuzaki and M. Mori, Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis, <em>Dig. Dis. Sci.</em> <bold>52</bold>(11) (2007) 3290–3295; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s10620-007-9808-2" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s10620-007-9808-2</a>">https://doi.org/10.1007/s10620-007-9808-2</ext-link>
    Search in Google ScholarBack to article
  8. L. C. Chen, W. Y. Chiou, H. Y. Lin, M. S. Lee, Y. C. Lo, L. W. Huang, C. M. Chang, T. H. Hung, C. W. Lin, K. C. Tseng, D. W. Liu, F. C. Hsu and S. K. Hung, Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial, <em>BMC Cancer</em> <bold>19</bold>(1) (2019) Article ID 275 (11 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1186/s12885-019-5461-3" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1186/s12885-019-5461-3</a>">https://doi.org/10.1186/s12885-019-5461-3</ext-link>
    Search in Google ScholarBack to article
  9. M. Reig, A. Forner, J. Rimola, J. Ferrer-Fàbrega, M. Burrel, Á. Garcia-Criado, R. K. Kelley, P. R. Galle, V. Mazzaferro, R. Salem, B. Sangro, A. G. Singal, A. Vogel, J. Fuster, C. Ayuso and J. Bruix, BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update, <em>J. Hepatol.</em> <bold>76</bold>(3) (2022) 681–693; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2021.11.018" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2021.11.018</a>">https://doi.org/10.1016/j.jhep.2021.11.018</ext-link>
    Search in Google ScholarBack to article
  10. H. Suzuki, M. Mori, C. Kawaguchi, M. Adachi, S. Miura and H. Ishii, Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma, <em>Int. J. Oncol.</em> <bold>14</bold>(6) (1999) 1087–1090; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3892/ijo.14.6.1087" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3892/ijo.14.6.1087</a>">https://doi.org/10.3892/ijo.14.6.1087</ext-link>
    Search in Google ScholarBack to article
  11. M. Kudo, K. Ueshima, M. Ikeda, T. Torimura, N. Tanabe, H. Aikata, N. Izumi, T. Yamasaki, S. Nojiri, K. Hino, H. Tsumura, T. Kuzuya, N. Isoda, K. Yasui, H. Aino, A. Ido, N. Kawabe, K. Nakao, Y. Wada, O. Yokosuka, K. Yoshimura, T. Okusaka, J. Furuse, N. Kokudo, K. Okita, P. J. Johnson and Y. Arai, Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial, <em>Gut</em> <bold>69</bold>(8) (2020) 1492–1501; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1136/gutjnl-2019-318934" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1136/gutjnl-2019-318934</a>">https://doi.org/10.1136/gutjnl-2019-318934</ext-link>
    Search in Google ScholarBack to article
  12. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition), <em>Zhonghua Gan Zang Bing Za Zhi</em> <bold>28</bold>(2) (2020) 112–128; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.004" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.004</a>">https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.004</ext-link>
    Search in Google ScholarBack to article
  13. S. Cheng, M. Chen, J. Cai, J. Sun, R. Guo, X. Bi, W. Y. Lau and M. Wu, Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 ed.), <em>Liver Cancer</em> <bold>9</bold>(1) (2020) 28–40; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1159/000503685" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1159/000503685</a>">https://doi.org/10.1159/000503685</ext-link>
    Search in Google ScholarBack to article
  14. R. Salem, D. Li, N. Sommer, S. Hernandez, W. Verret, B. Ding and R. Lencioni, Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial, <em>Cancer Med.</em> <bold>10</bold>(16) (2021) 5437–5447; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1002/cam4.4090" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/cam4.4090</a>">https://doi.org/10.1002/cam4.4090</ext-link>
    Search in Google ScholarBack to article
  15. 2018 Korean Liver Cancer Association – National Cancer Center Korea, Practice guidelines for the management of hepatocellular carcinoma, <em>Korean J. Radiol.</em> <bold>20</bold>(7) (2019) 1042–1113; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3348/kjr.2019.0140" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3348/kjr.2019.0140</a>">https://doi.org/10.3348/kjr.2019.0140</ext-link>
    Search in Google ScholarBack to article
  16. J. Yuan, X. Yin, B. Tang, H. Ma, L. Zhang, L. Li, R. Chen, X. Xie and Z. Ren, Transarterial Chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: A propensity score matching study, <em>Biomed. Res. Int.</em> <bold>2019</bold> (2019) Article ID 2141859 (6 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1155/2019/2141859" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1155/2019/2141859</a>">https://doi.org/10.1155/2019/2141859</ext-link>
    Search in Google ScholarBack to article
  17. Q. Chen and G. Zhang, Clinical efficacy and safety of TACE combined with sorafenib in the treatment of hepatocellular carcinoma with portal vein thrombus, <em>Chin. Hepatology</em> <bold>24</bold>(5) (2019) 573–576; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3969/j.issn.1008-1704.2019.05.032" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3969/j.issn.1008-1704.2019.05.032</a>">https://doi.org/10.3969/j.issn.1008-1704.2019.05.032</ext-link>
    Search in Google ScholarBack to article
  18. J. Wang, W. Chen, X. Liu and Y. Wu, Transcatheter arterial chemoembolization combined with sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombus, <em>Translat. Med. J.</em> <bold>6</bold>(03) (2017) 160–163.
    Search in Google ScholarBack to article
  19. Y. Zhang, Z. Gao, Y. Qian, M. Zhang, G. Tan and Z. Liu, Clinical effect analysis of sorafenib combined with TACE in the treatment of liver cancer with portal vein cancer thrombus, <em>Chin. J. Modern Drug Appl.</em> <bold>11</bold>(2017) 103–104; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.14164/j.cnki.cn11-5581/r.2017.19.055" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.14164/j.cnki.cn11-5581/r.2017.19.055</a>">https://doi.org/10.14164/j.cnki.cn11-5581/r.2017.19.055</ext-link>
    Search in Google ScholarBack to article
  20. A. Li, Evaluation of the clinical utility of TACE combined with sorafenib in the treatment of primary hepatocellular carcinoma with portal vein tumor thrombus, <em>Master Thesis</em>, 2017.
    Search in Google ScholarBack to article
  21. H.-H. Ye, J.-Z. Ye, Z.-B. Xie, Y.-C. Peng, J. Chen, L. Ma, T. Bai, J.-Z. Chen, Z. Lu, H.-G. Qin, B.-D. Xiang and L.-Q. Li, Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein, <em>World J. Gastroenter.</em> <bold>22</bold>(13) (2016) 3632–3643.
    Search in Google ScholarBack to article
  22. W. Li, Z. Dai, H. Wan, L. Yao, J. Zhu, C. Li, X. Wang, J. Pan and L. Chen, Endovascular implantation of iodine·125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus, <em>Nat. Med. J. China</em> <bold>96</bold>(2016) 1838–1842.
    Search in Google ScholarBack to article
  23. K. Wang, W. X. Guo, M. S. Chen, Y. L. Mao, B. C. Sun, J. Shi, Y. J. Zhang, Y. Meng, Y. F. Yang, W. M. Cong, M. C. Wu, W. Y. Lau and S. Q. Cheng, Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: A large-scale, multicenter, propensity mathching score analysis, <em>Medicine</em> (Baltimore) <bold>95</bold>(11) (2016) Article ID e3015 (10 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1097/MD.0000000000003015" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1097/MD.0000000000003015</a>">https://doi.org/10.1097/MD.0000000000003015</ext-link>
    Search in Google ScholarBack to article
  24. J. Hao, Hepatic arterial chemoembolization in combination with sorafenib for primary liver cancer with portal vein tumor thrombus, <em>Master Thesis,</em> 2015.
    Search in Google ScholarBack to article
  25. K. Zhu, J. Chen, L. Lai, X. Meng, B. Zhou, W. Huang, M. Cai and H. Shan, Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib – a retrospective controlled study, <em>Radiology</em> <bold>272</bold>(1) (2014) 284–293; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1148/radiol.14131946" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1148/radiol.14131946</a>">https://doi.org/10.1148/radiol.14131946</ext-link>
    Search in Google ScholarBack to article
  26. L. Luo and Z. Luo, Efficacy and safety analysis of sorafenib combined with TACE in the treatment of hepatocellular carcinoma with portal vein thrombus, <em>J. Chin. Physician</em> <bold>16</bold>(12) (2014) 1699–1701; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3760/cma.j.issn.1008-1372.2014.12.037" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3760/cma.j.issn.1008-1372.2014.12.037</a>">https://doi.org/10.3760/cma.j.issn.1008-1372.2014.12.037</ext-link>
    Search in Google ScholarBack to article
  27. J. Chen, W. Xi, B. Wu, H. Yu and S. Chen, Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis, <em>Chin. Med. J.</em> <bold>94</bold>(33) (2014) 2566–2569; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3760/cma.j.issn.0376-2491.2014.33.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3760/cma.j.issn.0376-2491.2014.33.003</a>">https://doi.org/10.3760/cma.j.issn.0376-2491.2014.33.003</ext-link>
    Search in Google ScholarBack to article
  28. A. R. Jadad, R. A. Moore, D. Carroll, C. Jenkinson, D. J. Reynolds, D. J. Gavaghan and H. J. McQuay, Assessing the quality of reports of randomized clinical trials: is blinding necessary? <em>Control. Clin. Trials</em> <bold>17</bold>(1) (1996) 1–12; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/0197-2456(95)00134-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/0197-2456(95)00134-4</a>">https://doi.org/10.1016/0197-2456(95)00134-4</ext-link>
    Search in Google ScholarBack to article
  29. J. Shi, E. C. Lai, N. Li, W. X. Guo, J. Xue, W. Y. Lau, M. C. Wu and S. Q. Cheng, A new classification for hepatocellular carcinoma with portal vein tumor thrombus, <em>J. Hepatobiliary Pancreat. Sci.</em> <bold>18</bold>(1) (2011) 74–80; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s00534-010-0314-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s00534-010-0314-0</a>">https://doi.org/10.1007/s00534-010-0314-0</ext-link>
    Search in Google ScholarBack to article
  30. J. Luo, R. P. Guo, E. C. Lai, Y. J. Zhang, W. Y. Lau, M. S. Chen and M. Shi, Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study, <em>Ann. Surg. Oncol.</em> <bold>18</bold>(2) (2011) 413–420; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1245/s10434-010-1321-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1245/s10434-010-1321-8</a>">https://doi.org/10.1245/s10434-010-1321-8</ext-link>
    Search in Google ScholarBack to article
  31. C. Shuqun, W. Mengchao, C. Han, S. Feng, Y. Jiahe, D. Guanghui, C. Wenming, W. Peijun and Z. Yuxiang, Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein, <em>Hepatogastroenterology</em> <bold>54</bold>(74) (2007) 499–502.
    Search in Google ScholarBack to article
  32. M. Abdelrahim, D. Victor, A. Esmail, S. Kodali, E. A. Graviss, D. T. Nguyen, L. W. Moore, A. Saharia, R. McMillan, J. N. Fong, A. Uosef, M. Elshawwaf, K. Heyne and R. M. Ghobrial, Transarterial chemoembolization (TACE) plus sorafenib compared to TACE alone in transplant recipients with hepatocellular carcinoma: An institution experience, <em>Cancers</em> (Basel) <bold>2022</bold>(14) (2022) Article ID 650 (13 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/cancers14030650" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/cancers14030650</a>">https://doi.org/10.3390/cancers14030650</ext-link>
    Search in Google ScholarBack to article
  33. S. W. Jeong, J. Y. Jang, K. Y. Shim, S. H. Lee, S. G. Kim, S. W. Cha, Y. S. Kim, Y. D. Cho, H. S. Kim, B. S. Kim, K. H. Kim and J. H. Kim, Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis, <em>Gut Liver.</em> <bold>7</bold>(6) (2013) 696–703; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.5009/gnl.2013.7.6.696" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.5009/gnl.2013.7.6.696</a>">https://doi.org/10.5009/gnl.2013.7.6.696</ext-link>
    Search in Google ScholarBack to article
  34. Z. B. Tan and J. Zhang, Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus, <em>Eur. Rev. Med. Pharmacol. Sci.</em> <bold>27</bold>(17) (2023) 8119–8134; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.26355/eurrev_202309_33572" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.26355/eurrev_202309_33572</a>">https://doi.org/10.26355/eurrev_202309_33572</ext-link>
    Search in Google ScholarBack to article
  35. Z. Peng, W. Fan, B. Zhu, G. Wang, J. Sun, C. Xiao, F. Huang, R. Tang, Y. Cheng, Z. Huang, Y. Liang, H. Fan, L. Qiao, F. Li, W. Zhuang, B. Peng, J. Wang, J. Li and M. Kuang, Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A Phase III, randomized clinical trial (LAUNCH), <em>J. Clin. Oncol.</em> <bold>41</bold>(1) (2023) 117–127; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1200/jco.22.00392" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1200/jco.22.00392</a>">https://doi.org/10.1200/jco.22.00392</ext-link>
    Search in Google ScholarBack to article
  36. J. Lu, J. H. Guo, J. S. Ji, Y. L. Li, W. F. Lv, H. D. Zhu, J. H. Sun, W. X. Ren, F. J. Zhang, W. D. Wang, H. B. Shao, G. S. Cao, H. L. Li, K. Gao, P. Yang, G. W. Yin, G. Y. Zhu, F. Z. Wu, W. J. Wang, D. Lu, S. Q. Chen, J. Min, Y. Zhao, R. Li, L. G. Lu, W. Y. Lau and G. J. Teng, Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial, <em>Int. J. Surg.</em> 109(5) (2023) 1188–1198; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1097/js9.0000000000000295" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1097/js9.0000000000000295</a>">https://doi.org/10.1097/js9.0000000000000295</ext-link>
    Search in Google ScholarBack to article
  37. X. Zou, Q. Xu, R. You and G. Yin, Evaluating the benefits of TACE combined with lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus, <em>Adv. Ther.</em> <bold>40</bold>(4) (2023) 1686–1704; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s12325-023-02449-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s12325-023-02449-6</a>">https://doi.org/10.1007/s12325-023-02449-6</ext-link>
    Search in Google ScholarBack to article
  38. M. Kudo, R. S. Finn, S. Qin, K. H. Han, K. Ikeda, F. Piscaglia, A. Baron, J. W. Park, G. Han, J. Jassem, J. F. Blanc, A. Vogel, D. Komov, T. R. J. Evans, C. Lopez, C. Dutcus, M. Guo, K. Saito, S. Kraljevic, T. Tamai, M. Ren and A. L. Cheng, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, <em>Lancet</em> <bold>391</bold>(10126) (2018) 1163–1173; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/s0140-6736(18)30207-1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/s0140-6736(18)30207-1</a>">https://doi.org/10.1016/s0140-6736(18)30207-1</ext-link>
    Search in Google ScholarBack to article
  39. A. Guerrero, L. D. Campo, F. Piscaglia, B. Scheiner, G. Han, F. Violi, C. N. Ferreira, L. Téllez, T. Reiberger, S. Basili, J. Zamora and A. Albillos, Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis, <em>J. Hepatol.</em> <bold>79</bold>(1) (2023) 69–78; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2023.02.023" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2023.02.023</a>">https://doi.org/10.1016/j.jhep.2023.02.023</ext-link>
    Search in Google ScholarBack to article
  40. M. Kicinski, D. A. Springate and E. Kontopantelis, Publication bias in meta-analyses from the Cochrane Database of Systematic Reviews, <em>Stat. Med.</em> <bold>34</bold>(20) (2015) 2781–2793; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1002/sim.6525" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/sim.6525</a>">https://doi.org/10.1002/sim.6525</ext-link>
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/acph-2024-0019 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 405 - 422
Accepted on: Apr 2, 2024
Published on: Sep 14, 2024
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
hepatocellular carcinoma,
portal vein tumor thrombosis,
transcatheter arterial chemoembolization,
sorafenib
Related subjects:
Pharmacy,
Pharmacy, other

© 2024 Li Xu, Shanshan Chen, Haijun Cao, Zemin Feng, Chao Yang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 74 (2024): Issue 3 (September 2024)Next article